No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
zanubrutinib
BeiGene Press Release - 1 week
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
brexucabtagene autoleucel
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax + ibrutinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
bendamustine
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
bortezomib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib + lenalidomide
Sensitive: A2 - Guideline
|
ALK negative
ALK negative
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
brentuximab vedotin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
VR-CAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-DHAP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-DHAX
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-CVAD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-GemOx
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: A2 - Guideline
|
CCR7 positive
CCR7 positive
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
brexucabtagene autoleucel
Sensitive: B - Late Trials
|
ABCB1 mutation + VEGFA mutation
ABCB1 mutation + VEGFA mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
VEGFA mutation
VEGFA mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
ABCB1 mutation
ABCB1 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
lenalidomide
Sensitive: B - Late Trials
|
CCND1 overexpression
CCND1 overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
INCB50465
Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: C2 – Inclusion Criteria
|
NLRC5 mutation
NLRC5 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
acalabrutinib
Resistant: C3 – Early Trials
|
B2M mutation
B2M mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
acalabrutinib
Resistant: C3 – Early Trials
|
CARD11 mutation
CARD11 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
acalabrutinib
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib + lenalidomide
Sensitive: C3 – Early Trials
|
PD-L1 underexpression
PD-L1 underexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
CDKN2A deletion
CDKN2A deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
Immunotherapy + lenalidomide
Resistant: C3 – Early Trials
|
ATM mutation
ATM mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
PRMT5 overexpression + MTAP deletion
PRMT5 overexpression + MTAP deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
CDKN2A deletion + MTAP deletion
CDKN2A deletion + MTAP deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
HES1 overexpression
HES1 overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: C3 – Early Trials
|
SOX11 expression
SOX11 expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: C3 – Early Trials
|
CTLA4 overexpression
CTLA4 overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: C3 – Early Trials
|
ITK overexpression
ITK overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
NOTCH1 mutation
NOTCH1 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib
Resistant: C3 – Early Trials
|
ARID1B deletion
ARID1B deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
temsirolimus
Resistant: C3 – Early Trials
|
DLGAP2 deletion
DLGAP2 deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
temsirolimus
Resistant: C3 – Early Trials
|
BIRC3 mutation
BIRC3 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
temsirolimus
Resistant: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + lenalidomide
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax + rituximab + lenalidomide
Sensitive: C3 – Early Trials
|
CD20 positive
CD20 positive
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
GEN3013
Sensitive: C3 – Early Trials
|
TP53 overexpression
TP53 overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
ibrutinib + bortezomib
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
rituximab + ibrutinib + EX-204
Sensitive: C3 – Early Trials
|
PIK3CD expression
PIK3CD expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
BI 6727
Sensitive: D – Preclinical
|
ROR1 expression
ROR1 expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
VLS-101
Sensitive: D – Preclinical
|
MYC overexpression
MYC overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
TG-1701
Sensitive: D – Preclinical
|
IL6 elevation
IL6 elevation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
TG-1701
Sensitive: D – Preclinical
|
IL2 elevation
IL2 elevation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
TG-1701
Sensitive: D – Preclinical
|
IL2 elevation
IL2 elevation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
|
IL6 elevation
IL6 elevation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
|
TNFA elevation
TNFA elevation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
umbralisib + TG-1701 + ublituximab
Sensitive: D – Preclinical
|
LY9 expression
LY9 expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
T-lymphocyte cell therapy
Sensitive: D – Preclinical
|
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
TG-1701
Sensitive: D – Preclinical
|
PIK3CG expression
PIK3CG expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib
Sensitive: D – Preclinical
|
PIK3CG expression
PIK3CG expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
BI 6727
Sensitive: D – Preclinical
|
PIK3CG expression
PIK3CG expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib + BI 6727
Sensitive: D – Preclinical
|
PIK3CD expression
PIK3CD expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib
Sensitive: D – Preclinical
|
PIK3CD expression
PIK3CD expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib + BI 6727
Sensitive: D – Preclinical
|
PIK3CB expression
PIK3CB expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib
Sensitive: D – Preclinical
|
PIK3CB expression
PIK3CB expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
BI 6727
Sensitive: D – Preclinical
|
PIK3CB expression
PIK3CB expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib + BI 6727
Sensitive: D – Preclinical
|
PIK3CA expression
PIK3CA expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib
Sensitive: D – Preclinical
|
PIK3CA expression
PIK3CA expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
copanlisib + BI 6727
Sensitive: D – Preclinical
|
PIK3CA expression
PIK3CA expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
BI 6727
Sensitive: D – Preclinical
|
BCL2L1 overexpression
BCL2L1 overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax
Resistant: D – Preclinical
|
SYK overexpression
SYK overexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
piceatannol
Sensitive: D – Preclinical
|
TP53 deletion
TP53 deletion
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
venetoclax
Resistant: D – Preclinical
|
CCND1 expression
CCND1 expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
palbociclib
Sensitive: D – Preclinical
|
ATM underexpression
ATM underexpression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
olaparib
Sensitive: D – Preclinical
|
CCND1 expression + CDK4 expression
CCND1 expression + CDK4 expression
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
palbociclib
Sensitive: D – Preclinical
|
NOTCH1 mutation
NOTCH1 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
Compound E
Sensitive: D – Preclinical
|
SAMHD1 mutation
SAMHD1 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
fludarabine IV
Resistant: D – Preclinical
|
SAMHD1 mutation
SAMHD1 mutation
|
Mantle Cell Lymphoma
Mantle Cell Lymphoma
|
cytarabine
Resistant: D – Preclinical
|
